BioAtla Investor Presentation Deck

CAB-AXL (BA3011) Phase 2, part 1 Topline Interim Analysis Results in Sarcoma Following BA3011 in remaining sarcoma subtypes Sarcoma Subtype # of Pt Leiomyosarcoma Synovial Liposarcoma Osteosarcoma Ewing sarcoma Bone Other: (Chondro/Chordo) Combo CD20 Positive Combo CD20 Negative bicatla 19 13 7 8 12 8 8/3 14 12 PFS rate 28.8% (Q2W) 10.3% (3Q4W)¹ 35.7% 62.5% 45.5% 18.8% 62.5%/66.7% 32.1% 41.7% ¹Low patient compliance PFS, progression-free survival; PR, partial response; UPS, undifferentiated pleomorphic sarcoma; NE, not evaluable Confidential Partial Response/ Complete Response 0 0 0 2 PRs 0 0 1 PR (UPS) 1 PR (LMS) 'Go' if ≥1 CR/PR or PFS rate at 3 months >40%; 'No Go' if 0 CR/PR and PFS rate at 3 months <40%; BioAtla| Overview 26

View entire presentation